Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.

The USA-based company was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which developed one of the world’s leading prostate cancer medicines.